At a glance
ClinicalIndex Comparison RecordN/ACompleted· 50 enrolled
Drug / intervention
Darbepoetin alfaother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients
In Brief
A clinical study evaluating Darbepoetin alfa for Anemia and End Stage Renal Failure on Dialysis. Completed, enrolled 50 participants across 1 site.
Detailed Summary
This is a prospective single-arm open-labeled cohort study on dialysis patients of the conversion from Aranesp® to NESP® for the treatment of anemia. The primary outcome of the study is the haemoglobin level after conversion to NESP® after 6 months. Secondary outcomes include the variability in haemoglobin level, average weekly dose of erythropoietin, safety profile of NESP®, patients' subjective assessment of fatigue and injection pain after the conversion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, End Stage Renal Failure on Dialysis
CountriesHong Kong
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartNov 2015
Primary CompletionNov 2017
TodayJul 2026
First PostedMay 12, 2015
Enrollment StartNov 1, 2015
Primary CompletionNov 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 11.1 years ago
Interventions
Darbepoetin alfaother
Conversion from Aranesp® to NESP®